Cited by 47Ovarian function and disordersReproductive Health and TechnologiesReproductive Biology and Fertility

New advances in ovulation induction

Kafy, Souzan, Tulandi, Togas·2007·Current Opinion in Obstetrics & Gynecology

Abstract

PURPOSE OF REVIEW: To review recent advances in ovulation induction. RECENT FINDINGS: Aromatase inhibitors can replace clomiphene citrate as ovulation-inducing substances. The most widely used aromatase inhibitor for this purpose is letrozole and the optimal dose is 5 mg daily for 5 days. Compared to clomiphene citrate, it is associated with a thicker endometrium and a better pregnancy rate. It is as effective as gonadotropin but yet less expensive. The overall rates of congenital malformation among newborns conceived after infertility treatment with letrozole or clomiphene citrate are similar. When letrozole is combined with gonadotropin, it leads to lower gonadotropin requirements with pregnancy rates comparable to gonadotropin treatment alone. Another promising aromatase inhibitor is anastrazole. Recent evidence suggests that luteinizing hormone activity in human menopausal gonadotropin modifies follicular development so that fewer intermediate-sized follicles develop. Compared to the use of follicular stimulating hormone only, human menopausal gonadotropin is associated with less ovarian hyperstimulation. SUMMARY: Aromatase inhibitors are alternative drugs to clomiphene or gonadotropin for ovulation induction or superovulation.

Integrity signals

Registry

Crossref · 10.1097/gco.0b013e3280c60c9a

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kafy, S., & Tulandi, T.
Affiliations
McGill University (CA)
Corresponding author
Tulandi, Togas
Venue
Current Opinion in Obstetrics & Gynecology
Published
2007-06
Volume
19
Issue
3
Pages
248-252
ISSN
1040-872X (ISSN-L)
OpenAlex
W2062827277
Cited by
47
References
26
Citations by year
2026: 2 · 2025: 2 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 5 · 2017: 2 · 2015: 1 · 2014: 1 · 2013: 3 · 2012: 3
FWCI
4.40
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Obstetrics & Gynecology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Biology and Fertility
Keywords
ovulation induction, aromatase inhibitors, letrozole, clomiphene citrate, anastrozole, gonadotropins, human menopausal gonadotropin, superovulation, ovarian hyperstimulation, endometrial thickness, pregnancy rate, congenital malformations, infertility treatment
MeSH terms
Letrozole, Anastrozole, Clomiphene, Estrogen Antagonists, Female, Fertility Agents, Female, Gonadotropins, Humans, Infertility, Female, Nitriles, Ovary, Ovulation Induction, Pregnancy, Tamoxifen, Triazoles, Treatment Outcome, Pregnancy Rate, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review